Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00428090 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

862

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Rosiglitazone

Sponsor

GlaxoSmithKline